Media inquiries

media@disarmtx.com
+1.202.930.4762

Press releases

January 23, 2018 – Disarm Therapeutics Appoints Thomas Engber as Senior Vice President, Head of Neuropharmacology and Translational Sciences

December 19, 2017 – Disarm Therapeutics Appoints Peter Keller Chief Business Officer

September 19, 2017 Disarm Therapeutics Unveils Breakthrough Approach to Treat Patients with Neurological Diseases by Preventing Axonal Degeneration
Announces $30 Million Series A Financing Led by Atlas Venture, with Co-Investors Lightstone Ventures and AbbVie Ventures

Publications

Sarm1 Deletion, but Not WldS, Confers Lifelong Rescue in a Mouse Model of Severe Axonopathy
Gilley J, Ribchester R, Coleman M.
Cell Rep. 2017 Oct 3;21(1):10-16.

The SARM1 Toll/Interleukin-1 Receptor Domain Possesses Intrinsic NAD+ Cleavage Activity that Promotes Pathological Axonal Degeneration.
Essuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J.
Neuron. 2017 Mar 22;93(6):1334-1343.

SARM1-specific motifs in the TIR domain enable NAD+ loss and regulate injury-induced SARM1 activation.
Summers DW, Gibson DA, DiAntonio A, Milbrandt J.
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):E6271-E6280.

Axon Self-Destruction: New Links among SARM1, MAPKs, and NAD+ Metabolism.
Gerdts J, Summers DW, Milbrandt J, DiAntonio A.
Neuron. 2016 Feb 3;89(3):449-60.

SARM1 activation triggers axon degeneration locally via NAD⁺ destruction.
Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J.
Science. 2015 Apr 24;348(6233):453-7.

Mitochondrial dysfunction induces Sarm1-dependent cell death in sensory neurons.
Summers DW, DiAntonio A, Milbrandt J.
J Neurosci. 2014 Jul 9;34(28):9338-50.

Sarm1-mediated axon degeneration requires both SAM and TIR interactions.
Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J.
J Neurosci. 2013 Aug 14;33(33):13569-80.